Inpatient Diuretic Management of Acute Heart Failure: A Practical Review.
Journal
American journal of cardiovascular drugs : drugs, devices, and other interventions
ISSN: 1179-187X
Titre abrégé: Am J Cardiovasc Drugs
Pays: New Zealand
ID NLM: 100967755
Informations de publication
Date de publication:
Nov 2021
Nov 2021
Historique:
accepted:
10
12
2020
pubmed:
13
3
2021
medline:
24
12
2021
entrez:
12
3
2021
Statut:
ppublish
Résumé
The inpatient treatment of acute heart failure (AHF) is aimed at achieving euvolemia, relieving symptoms, and reducing rehospitalization. Adequate treatment of AHF is rooted in understanding the pharmacokinetics and pharmacodynamics of select diuretic agents used to achieve decongestion. While loop diuretics remain the primary treatment of AHF, the dosing strategies of loop diuretics and the use of adjunct diuretic classes to augment clinical response can be complex. This review examines the latest strategies for diuretic management in patients with AHF, including dosing and monitoring strategies, interaction of diuretics with other medication classes, use adjunctive therapies, and assessing endpoints for diuretic. The goal of the review is to guide the reader through commonly encountered clinical scenarios and pitfalls in the diuretic management of patients with AHF.
Identifiants
pubmed: 33709346
doi: 10.1007/s40256-020-00463-5
pii: 10.1007/s40256-020-00463-5
doi:
Substances chimiques
Diuretics
0
Sodium Potassium Chloride Symporter Inhibitors
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
595-608Subventions
Organisme : Special Research Fund of Hasselt University
ID : BOF19PD04
Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer Nature Switzerland AG part of Springer Nature.
Références
Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;62(16):e147–239. https://doi.org/10.1016/j.jacc.2013.05.019 .
doi: 10.1016/j.jacc.2013.05.019
pubmed: 23747642
Peacock WF, Costanzo MR, De Marco T, et al. Impact of intravenous loop diuretics on outcomes of patients hospitalized with acute decompensated heart failure: insights from the ADHERE registry. Cardiology. 2009;113(1):12–9. https://doi.org/10.1159/000164149 .
doi: 10.1159/000164149
pubmed: 18931492
Casu G, Merella P. Diuretic therapy in heart failure—current approaches. Eur Cardiol. 2015;10(1):42–7. https://doi.org/10.15420/ecr.2015.10.01.42 .
doi: 10.15420/ecr.2015.10.01.42
pubmed: 30310422
pmcid: 6159465
Wile D. Diuretics: a review. Ann Clin Biochem. 2012;49(Pt 5):419–31. https://doi.org/10.1258/acb.2011.011281 .
doi: 10.1258/acb.2011.011281
pubmed: 22783025
Francis GS, Siegel RM, Goldsmith SR, Olivari MT, Levine TB, Cohn JN. Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart failure. Activation of the neurohumoral axis. Ann Intern Med. 1985;103(1):1–6. https://doi.org/10.7326/0003-4819-103-1-1 .
Singh P, Okusa MD. The role of tubuloglomerular feedback in the pathogenesis of acute kidney injury. Contrib Nephrol. 2011;174:12–21. https://doi.org/10.1159/000329229 .
doi: 10.1159/000329229
pubmed: 21921605
Sambandam KK. Effective use of loop diuretics in heart failure exacerbation: a nephrologist’s view. Am J Med Sci. 2014;347(2):139–45. https://doi.org/10.1097/MAJ.0b013e31828a2962 .
doi: 10.1097/MAJ.0b013e31828a2962
pubmed: 23588260
Ellison DH. Clinical Pharmacology in Diuretic Use [published correction appears in Clin J Am Soc Nephrol. 2019 Nov;14(11):1653-1654]. Clin J Am Soc Nephrol. 2019;14(8):1248–1257. https://doi.org/10.2215/cjn.09630818 .
Beermann B, Grind M. Clinical pharmacokinetics of some newer diuretics. Clin Pharmacokinet. 1987;13(4):254–66. https://doi.org/10.2165/00003088-198713040-00003 .
doi: 10.2165/00003088-198713040-00003
pubmed: 3311532
Carone L, Oxberry SG, Twycross R, Charlesworth S, Mihalyo M, Wilcock A. Furosemide. J Pain Symptom Manage. 2016;52(1):144–50. https://doi.org/10.1016/j.jpainsymman.2016.05.004 .
doi: 10.1016/j.jpainsymman.2016.05.004
pubmed: 27238657
Hammarlund MM, Paalzow LK, Odlind B. Pharmacokinetics of furosemide in man after intravenous and oral administration. Application of moment analysis. Eur J Clin Pharmacol. 1984;26(2):197–207. https://doi.org/10.1007/bf00630286 .
Brater DC. Diuretic therapy. N Engl J Med. 1998;339(6):387–95. https://doi.org/10.1056/NEJM199808063390607 .
doi: 10.1056/NEJM199808063390607
pubmed: 9691107
Sunkara B, Dorsch M, Nicklar J, Nicklas J M. Voluminous responses to loop diuretics are safe in patients with acute decompensated heart failure and chronic kidney disease. Circulation. In: Proceedings from AHA Scientific Sessions 2018. 2018. Abstract 16500.
Baldwin KA, Budzinski CE, Shapiro CJ. Acute sensorineural hearing loss: furosemide ototoxicity revisited. Hosp Pharm. 2008;43(12):982–8. https://doi.org/10.1310/hpj4312-982 .
doi: 10.1310/hpj4312-982
Bumetanide. AHFS Drug Information 2010. AHFS Clinical Drug Information. Bethesda, MD: American Society of Health-System Pharmacists, Inc. Updated January 2009.
Wargo KA, Banta WM. A comprehensive review of the loop diuretics: should furosemide be first line? Ann Pharmacother. 2009;43(11):1836–47. https://doi.org/10.1345/aph.1M177 .
doi: 10.1345/aph.1M177
pubmed: 19843838
DiNicolantonio JJ. Should torsemide be the loop diuretic of choice in systolic heart failure? Future Cardiol. 2012;8(5):707–28. https://doi.org/10.2217/fca.12.54 .
doi: 10.2217/fca.12.54
pubmed: 23013124
Murray MD, Deer MM, Ferguson JA, et al. Open-label randomized trial of torsemide compared with furosemide therapy for patients with heart failure. Am J Med. 2001;111(7):513–20. https://doi.org/10.1016/s0002-9343(01)00903-2 .
doi: 10.1016/s0002-9343(01)00903-2
pubmed: 11705426
Cosín J, Díez J; TORIC investigators. Torsemide in chronic heart failure: results of the TORIC study [published correction appears in Eur J Heart Fail 2002 Oct;4(5):667]. Eur J Heart Fail. 2002;4(4):507–513. https://doi.org/10.1016/s1388-9842(02)00122-8 .
Testani JM, Brisco MA, Turner JM, et al. Loop diuretic efficiency: a metric of diuretic responsiveness with prognostic importance in acute decompensated heart failure. Circ Heart Fail. 2014;7(2):261–70. https://doi.org/10.1161/CIRCHEARTFAILURE.113.000895 .
doi: 10.1161/CIRCHEARTFAILURE.113.000895
pubmed: 24379278
Vasko MR, Cartwright DB, Knochel JP, Nixon JV, Brater DC. Furosemide absorption altered in decompensated congestive heart failure. Ann Intern Med. 1985;102(3):314–8. https://doi.org/10.7326/0003-4819-102-3-314 .
doi: 10.7326/0003-4819-102-3-314
pubmed: 3970471
Berkowtiz D, Croll MN, Likoff W. Malabsorption as a complication of congestive heart failure. Am J Cardiol. 1963;11:43–7. https://doi.org/10.1016/0002-9149(63)90029-8 .
doi: 10.1016/0002-9149(63)90029-8
Felker GM, Lee KL, Bull DA, et al. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med. 2011;364(9):797–805. https://doi.org/10.1056/NEJMoa1005419 .
doi: 10.1056/NEJMoa1005419
pubmed: 21366472
pmcid: 3412356
Mullens W, Damman K, Harjola VP, et al. The use of diuretics in heart failure with congestion—a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2019;21(2):137–55. https://doi.org/10.1002/ejhf.1369 .
doi: 10.1002/ejhf.1369
pubmed: 30600580
Verbrugge FH. Utility of urine biomarkers and electrolytes for the management of heart failure. Curr Heart Fail Rep. 2019;16(6):240–9. https://doi.org/10.1007/s11897-019-00444-z .
doi: 10.1007/s11897-019-00444-z
pubmed: 31741232
Palazzuoli A, Pellegrini M, Ruocco G, et al. Continuous versus bolus intermittent loop diuretic infusion in acutely decompensated heart failure: a prospective randomized trial. Crit Care. 2014;18(3):R134. https://doi.org/10.1186/cc13952 .
Ng KT, Velayit A, Khoo DKY, Mohd Ismail A, Mansor M. Continuous infusion versus intermittent bolus injection of furosemide in critically ill patients: a systematic review and meta-analysis. J Cardiothorac Vasc Anesth. 2018;32(5):2303–10. https://doi.org/10.1053/j.jvca.2018.01.004 .
doi: 10.1053/j.jvca.2018.01.004
pubmed: 29454528
Verbrugge FH, Tang WH, Mullens W. Renin-Angiotensin-aldosterone system activation during decongestion in acute heart failure: friend or foe? JACC Heart Fail. 2015;3(2):108–11. https://doi.org/10.1016/j.jchf.2014.10.005 .
doi: 10.1016/j.jchf.2014.10.005
pubmed: 25543974
Mentz RJ, Stevens SR, DeVore AD, et al. Decongestion strategies and renin-angiotensin-aldosterone system activation in acute heart failure. JACC Heart Fail. 2015;3(2):97–107. https://doi.org/10.1016/j.jchf.2014.09.003 .
doi: 10.1016/j.jchf.2014.09.003
pubmed: 25543972
Frea S, Pidello S, Volpe A, et al. Diuretic treatment in high-risk acute decompensation of advanced chronic heart failure-bolus intermittent vs. continuous infusion of furosemide: a randomized controlled trial. Clin Res Cardiol. 2020;109(4):417–425. https://doi.org/10.1007/s00392-019-01521-y .
Jenkins PG. Diuretic strategies in patients with acute heart failure. N Engl J Med. 2011;364(21):2066–9. https://doi.org/10.1056/NEJMc1103708 .
doi: 10.1056/NEJMc1103708
pubmed: 21612482
Abi Khalil C, Al Suwaidi J, Singh R, et al. Beta-blockers are associated with decreased in-hospital mortality and stroke in acute decompensated heart failure: findings from a retrospective analysis of a 22-year registry in the middle east (1991–2013). Curr Vasc Pharmacol. 2017;15(1):77–83. https://doi.org/10.2174/1570161114666160822155440 .
doi: 10.2174/1570161114666160822155440
pubmed: 27550053
Jondeau G, Neuder Y, Eicher JC, et al. B-CONVINCED: Beta-blocker CONtinuation Vs. INterruption in patients with Congestive heart failure hospitalizED for a decompensation episode. Eur Heart J. 2009;30(18):2186-2192. https://doi.org/10.1093/eurheartj/ehp323 .
Darden D, Drazner MH, Mullens W, Dupont M, Tang WHW, Grodin JL. Implications of renin-angiotensin-system blocker discontinuation in acute decompensated heart failure with systolic dysfunction. Clin Cardiol. 2019;42(10):1010–8. https://doi.org/10.1002/clc.23260 .
doi: 10.1002/clc.23260
pubmed: 31498919
pmcid: 6788475
Beusekamp JC, Tromp J, Cleland JGF, et al. Hyperkalemia and treatment with RAAS inhibitors during acute heart failure hospitalizations and their association with mortality. JACC Heart Fail. 2019;7(11):970–9. https://doi.org/10.1016/j.jchf.2019.07.010 .
doi: 10.1016/j.jchf.2019.07.010
pubmed: 31606364
Fonarow GC, Abraham WT, Albert NM, et al. Influence of beta-blocker continuation or withdrawal on outcomes in patients hospitalized with heart failure: findings from the OPTIMIZE-HF program. J Am Coll Cardiol. 2008;52(3):190–9. https://doi.org/10.1016/j.jacc.2008.03.048 .
doi: 10.1016/j.jacc.2008.03.048
pubmed: 18617067
Butler J, Young JB, Abraham WT, et al. Beta-blocker use and outcomes among hospitalized heart failure patients. J Am Coll Cardiol. 2006;47(12):2462–9. https://doi.org/10.1016/j.jacc.2006.03.030 .
doi: 10.1016/j.jacc.2006.03.030
pubmed: 16781374
Testani JM, Brisco MA, Kociol RD, et al. Substantial discrepancy between fluid and weight loss during acute decompensated heart failure treatment. Am J Med. 2015;128(7):776–783.e4. https://doi.org/10.1016/j.amjmed.2014.12.020 .
doi: 10.1016/j.amjmed.2014.12.020
pubmed: 25595470
pmcid: 4475432
Vazir A, Cowie MR. Decongestion: diuretics and other therapies for hospitalized heart failure. Indian Heart J. 2016;68 Suppl 1(Suppl 1):S61–S68. https://doi.org/10.1016/j.ihj.2015.10.386 .
Testani JM, Hanberg JS, Cheng S, et al. Rapid and highly accurate prediction of poor loop diuretic natriuretic response in patients with heart failure. Circ Heart Fail. 2016;9(1):e002370. https://doi.org/10.1161/CIRCHEARTFAILURE.115.002370 .
doi: 10.1161/CIRCHEARTFAILURE.115.002370
pubmed: 26721915
pmcid: 4741370
Luk A, Groarke JD, Desai AS, et al. First spot urine sodium after initial diuretic identifies patients at high risk for adverse outcome after heart failure hospitalization. Am Heart J. 2018;203:95–100. https://doi.org/10.1016/j.ahj.2018.01.013 .
doi: 10.1016/j.ahj.2018.01.013
pubmed: 29907406
Hodson DZ, Griffin M, Mahoney D, et al. Natriuretic response is highly variable and associated with 6-month survival: insights from the ROSE-AHF trial. JACC Heart Fail. 2019;7(5):383–91. https://doi.org/10.1016/j.jchf.2019.01.007 .
doi: 10.1016/j.jchf.2019.01.007
pubmed: 31047017
pmcid: 6501816
Singh D, Shrestha K, Testani JM, et al. Insufficient natriuretic response to continuous intravenous furosemide is associated with poor long-term outcomes in acute decompensated heart failure. J Card Fail. 2014;20(6):392–9. https://doi.org/10.1016/j.cardfail.2014.03.006 .
doi: 10.1016/j.cardfail.2014.03.006
pubmed: 24704538
pmcid: 4067259
Verbrugge FH, Dupont M, Bertrand PB, et al. Determinants and impact of the natriuretic response to diuretic therapy in heart failure with reduced ejection fraction and volume overload. Acta Cardiol. 2015;70(3):265–73. https://doi.org/10.1080/ac.70.3.3080630 .
doi: 10.1080/ac.70.3.3080630
pubmed: 26226699
Roush GC, Kaur R, Ernst ME. Diuretics: a review and update. J Cardiovasc Pharmacol Ther. 2014;19(1):5–13. https://doi.org/10.1177/1074248413497257 .
doi: 10.1177/1074248413497257
pubmed: 24243991
Li X, Wang R, Liu Y, et al. Pharmacokinetic study of single- and multiple-dosing with metolazone tablets in healthy Chinese population. BMC Pharmacol Toxicol. 2017;18(1):73. https://doi.org/10.1186/s40360-017-0178-x .
Colussi D, Schoeller JP, Richard A, Sioufi A. Pharmacokinetics of chlorthalidone in the elderly after single and multiple doses. Br J Clin Pharmacol. 1983;16(6):755–6. https://doi.org/10.1111/j.1365-2125.1983.tb02259.x .
doi: 10.1111/j.1365-2125.1983.tb02259.x
pubmed: 6661366
pmcid: 1428332
Jentzer JC, DeWald TA, Hernandez AF. Combination of loop diuretics with thiazide-type diuretics in heart failure. J Am Coll Cardiol. 2010;56(19):1527–34. https://doi.org/10.1016/j.jacc.2010.06.034 .
doi: 10.1016/j.jacc.2010.06.034
pubmed: 21029871
Sica DA. Metolazone and its role in edema management. Congest Heart Fail. 2003;9(2):100–5. https://doi.org/10.1111/j.1527-5299.2003.01907.x .
doi: 10.1111/j.1527-5299.2003.01907.x
pubmed: 12671341
Brisco-Bacik MA, Ter Maaten JM, Houser SR, et al. Outcomes associated with a strategy of adjuvant metolazone or high-dose loop diuretics in acute decompensated heart failure: a propensity analysis. J Am Heart Assoc. 2018;7(18):e009149. https://doi.org/10.1161/JAHA.118.009149 .
doi: 10.1161/JAHA.118.009149
pubmed: 30371181
pmcid: 6222930
Verbrugge FH, Martens P, Ameloot K, et al. Spironolactone to increase natriuresis in congestive heart failure with cardiorenal syndrome. Acta Cardiol. 2019;74(2):100–7. https://doi.org/10.1080/00015385.2018.1455947 .
doi: 10.1080/00015385.2018.1455947
pubmed: 29587582
Butler J, Anstrom KJ, Felker GM, et al. Efficacy and safety of spironolactone in acute heart failure: the ATHENA-HF randomized clinical trial. JAMA Cardiol. 2017;2(9):950–8. https://doi.org/10.1001/jamacardio.2017.2198 .
doi: 10.1001/jamacardio.2017.2198
pubmed: 28700781
pmcid: 5675712
Hampson AJ, Babalonis S, Lofwall MR, Nuzzo PA, Krieter P, Walsh SL. A pharmacokinetic study examining acetazolamide as a novel adherence marker for clinical trials. J Clin Psychopharmacol. 2016;36(4):324–32. https://doi.org/10.1097/JCP.0000000000000529 .
doi: 10.1097/JCP.0000000000000529
pubmed: 27300254
pmcid: 5360176
Imiela T, Budaj A. Acetazolamide as add-on diuretic therapy in exacerbations of chronic heart failure: a pilot study. Clin Drug Investig. 2017;37(12):1175–81. https://doi.org/10.1007/s40261-017-0577-1 .
doi: 10.1007/s40261-017-0577-1
pubmed: 28965280
pmcid: 5684277
Verbrugge FH, Martens P, Ameloot K, et al. Acetazolamide to increase natriuresis in congestive heart failure at high risk for diuretic resistance. Eur J Heart Fail. 2019;21(11):1415–22. https://doi.org/10.1002/ejhf.1478 .
doi: 10.1002/ejhf.1478
pubmed: 31074184
Wongboonsin J, Thongprayoon C, Bathini T, et al. Acetazolamide therapy in patients with heart failure: a meta-analysis. J Clin Med. 2019;8(3):349. https://doi.org/10.3390/jcm8030349 .
Carbonic Anhydrase Inhibitors General Statement. AHFS Drug Information 2010. AHFS Clinical Drug Information. Bethesda, MD: American Society of Health-System Pharmacists, Inc. Updated January 2009.
Mullens W, Verbrugge FH, Nijst P, et al. Rationale and design of the ADVOR (Acetazolamide in Decompensated Heart Failure with Volume Overload) trial. Eur J Heart Fail. 2018;20(11):1591–600. https://doi.org/10.1002/ejhf.1307 .
doi: 10.1002/ejhf.1307
pubmed: 30238574
Felker GM, Mentz RJ, Cole RT, et al. Efficacy and safety of tolvaptan in patients hospitalized with acute heart failure. J Am Coll Cardiol. 2017;69(11):1399–406. https://doi.org/10.1016/j.jacc.2016.09.004 .
doi: 10.1016/j.jacc.2016.09.004
pubmed: 27654854
Cox ZL, Hung R, Lenihan DJ, Testani JM. Diuretic strategies for loop diuretic resistance in acute heart failure: the 3T trial. JACC Heart Fail. 2020;8(3):157–68. https://doi.org/10.1016/j.jchf.2019.09.012 .
doi: 10.1016/j.jchf.2019.09.012
pubmed: 31838029
Konstam MA, Gheorghiade M, Burnett JC Jr, et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA. 2007;297(12):1319–31. https://doi.org/10.1001/jama.297.12.1319 .
doi: 10.1001/jama.297.12.1319
pubmed: 17384437
Ansary TM, Nakano D, Nishiyama A. Diuretic effects of sodium glucose cotransporter 2 inhibitors and their influence on the renin-angiotensin system. Int J Mol Sci. 2019;20(3):629. https://doi.org/10.3390/ijms20030629 .
Sha S, Polidori D, Heise T, et al. Effect of the sodium glucose co-transporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2014;16(11):1087–95. https://doi.org/10.1111/dom.12322 .
doi: 10.1111/dom.12322
pubmed: 24939043
Ohara K, Masuda T, Murakami T, et al. Effects of the sodium-glucose cotransporter 2 inhibitor dapagliflozin on fluid distribution: a comparison study with furosemide and tolvaptan. Nephrology (Carlton). 2019;24(9):904–11. https://doi.org/10.1111/nep.13552 .
doi: 10.1111/nep.13552
pubmed: 30578654
Wilcox CS, Shen W, Boulton DW, Leslie BR, Griffen SC. Interaction between the sodium-glucose-linked transporter 2 inhibitor dapagliflozin and the loop diuretic bumetanide in normal human subjects. J Am Heart Assoc. 2018;7(4):e007046. https://doi.org/10.1161/jaha.117.007046 .
Griffin M, Rao VS, Ivey-Miranda J, et al. Empagliflozin in Heart Failure: Diuretic and Cardio-Renal Effects [published online ahead of print, 2020 May 15]. Circulation. 2020; https://doi.org/10.1161/circulationaha.120.045691 .
Damman K, Beusekamp JC, Boorsma EM, et al. Randomized, double-blind, placebo-controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA-RESPONSE-AHF). Eur J Heart Fail. 2020;22(4):713–22. https://doi.org/10.1002/ejhf.1713 .
doi: 10.1002/ejhf.1713
pubmed: 31912605
Lindenfield J, Cox Z, Collins S. (2020). [Clinical trial investigating the Efficacy and Safety of Dapagliflozin in Acute Heart Failure- DICTATE-AHF]. NCT04298229.
Lehrke M, Marx N. (2019). [Clinical trial EMPA Acute Heart Failure]. NCT03554200.
Elkayam U, Ng TM, Hatamizadeh P, Janmohamed M, Mehra A. Renal vasodilatory action of dopamine in patients with heart failure: magnitude of effect and site of action. Circulation. 2008;117(2):200–5. https://doi.org/10.1161/CIRCULATIONAHA.107.737106 .
doi: 10.1161/CIRCULATIONAHA.107.737106
pubmed: 18172028
Giamouzis G, Butler J, Starling RC, et al. Impact of dopamine infusion on renal function in hospitalized heart failure patients: results of the Dopamine in Acute Decompensated Heart Failure (DAD-HF) Trial. J Card Fail. 2010;16(12):922–30. https://doi.org/10.1016/j.cardfail.2010.07.246 .
doi: 10.1016/j.cardfail.2010.07.246
pubmed: 21111980
Triposkiadis FK, Butler J, Karayannis G, et al. Efficacy and safety of high dose versus low dose furosemide with or without dopamine infusion: the Dopamine in Acute Decompensated Heart Failure II (DAD-HF II) trial. Int J Cardiol. 2014;172(1):115–21. https://doi.org/10.1016/j.ijcard.2013.12.276 .
doi: 10.1016/j.ijcard.2013.12.276
pubmed: 24485633
Chen HH, Anstrom KJ, Givertz MM, et al. Low-dose dopamine or low-dose nesiritide in acute heart failure with renal dysfunction: the ROSE acute heart failure randomized trial. JAMA. 2013;310(23):2533–43. https://doi.org/10.1001/jama.2013.282190 .
doi: 10.1001/jama.2013.282190
pubmed: 24247300
pmcid: 3934929
Wan SH, Stevens SR, Borlaug BA, et al. Differential response to low-dose dopamine or low-dose nesiritide in acute heart failure with reduced or preserved ejection fraction: results from the ROSE AHF trial (renal optimization strategies evaluation in acute heart failure). Circ Heart Fail. 2016;9(8):e002593. https://doi.org/10.1161/circheartfailure.115.002593 .
Rajfer SI, Borow KM, Lang RM, Neumann A, Carroll JD. Effects of dopamine on left ventricular afterload and contractile state in heart failure: relation to the activation of beta 1-adrenoceptors and dopamine receptors. J Am Coll Cardiol. 1988;12(2):498–506. https://doi.org/10.1016/0735-1097(88)90426-3 .
doi: 10.1016/0735-1097(88)90426-3
pubmed: 2839569
Licata G, Di Pasquale P, Parrinello G, et al. Effects of high-dose furosemide and small-volume hypertonic saline solution infusion in comparison with a high dose of furosemide as bolus in refractory congestive heart failure: long-term effects. Am Heart J. 2003;145(3):459–66. https://doi.org/10.1067/mhj.2003.166 .
doi: 10.1067/mhj.2003.166
pubmed: 12660669
Paterna S, Di Pasquale P, Parrinello G, et al. Changes in brain natriuretic peptide levels and bioelectrical impedance measurements after treatment with high-dose furosemide and hypertonic saline solution versus high-dose furosemide alone in refractory congestive heart failure: a double-blind study. J Am Coll Cardiol. 2005;45(12):1997–2003. https://doi.org/10.1016/j.jacc.2005.01.059 .
doi: 10.1016/j.jacc.2005.01.059
pubmed: 15963399
Paterna S, Fasullo S, Parrinello G, et al. Short-term effects of hypertonic saline solution in acute heart failure and long-term effects of a moderate sodium restriction in patients with compensated heart failure with New York Heart Association class III (Class C) (SMAC-HF Study). Am J Med Sci. 2011;342(1):27–37. https://doi.org/10.1097/MAJ.0b013e31820f10ad .
doi: 10.1097/MAJ.0b013e31820f10ad
pubmed: 21701268
Kitsios GD, Mascari P, Ettunsi R, Gray AW. Co-administration of furosemide with albumin for overcoming diuretic resistance in patients with hypoalbuminemia: a meta-analysis. J Crit Care. 2014;29(2):253–9. https://doi.org/10.1016/j.jcrc.2013.10.004 .
doi: 10.1016/j.jcrc.2013.10.004
pubmed: 24268626
Oczkowski SJW, Klotz L, Mazzetti I, et al. Furosemide and Albumin for Diuresis of Edema (FADE): a parallel-group, blinded, pilot randomized controlled trial. J Crit Care. 2018;48:462–7. https://doi.org/10.1016/j.jcrc.2018.07.020 .
doi: 10.1016/j.jcrc.2018.07.020
pubmed: 30037660
Mahmoodpoor A, Zahedi S, Pourakbar A, et al. Efficacy of furosemide-albumin compared with furosemide in critically ill hypoalbuminemia patients admitted to intensive care unit: a prospective randomized clinical trial. Daru. 2020;28(1):263–9. https://doi.org/10.1007/s40199-020-00339-8 .
doi: 10.1007/s40199-020-00339-8
pubmed: 32291620
pmcid: 7214594
Liu C, Chen Y, Kang Y, Ni Z, Xiu H, Guan J, Liu K. Glucocorticoids improve renal responsiveness to atrial natriuretic peptide by up-regulating natriuretic peptide receptor-A expression in the renal inner medullary collecting duct in decompensated heart failure. J Pharmacol Exp Ther. 2011;339(1):203–9. https://doi.org/10.1124/jpet.111.184796 Epub 2011 Jul 7 PMID: 21737535.
doi: 10.1124/jpet.111.184796
pubmed: 21737535
Liu C, Liu K. Effects of glucocorticoids in potentiating diuresis in heart failure patients with diuretic resistance. J Card Fail. 2014;20(9):625–9. https://doi.org/10.1016/j.cardfail.2014.06.353 Epub 2014 Jun 23 PMID: 24969700.
doi: 10.1016/j.cardfail.2014.06.353
pubmed: 24969700
Bart BA, Goldsmith SR, Lee KL, Givertz MM, O’Connor CM, Bull DA, Redfield MM, Deswal A, Rouleau JL, LeWinter MM, Ofili EO, Stevenson LW, Semigran MJ, Felker GM, Chen HH, Hernandez AF, Anstrom KJ, McNulty SE, Velazquez EJ, Ibarra JC, Mascette AM, Braunwald E; Heart Failure Clinical Research Network. Ultrafiltration in decompensated heart failure with cardiorenal syndrome. N Engl J Med. 2012;367(24):2296–304. https://doi.org/10.1056/nejmoa1210357 (Epub 2012 Nov 6).
Kabach M, Alkhawam H, Shah S, Joseph G, Donath EM, Moss N, Rosenstein RS, Chait R. Ultrafiltration versus intravenous loop diuretics in patients with acute decompensated heart failure: a meta-analysis of clinical trials. Acta Cardiol. 2017;72(2):132–41. https://doi.org/10.1080/00015385.2017.1291195 (Epub 2017 Feb 28).
doi: 10.1080/00015385.2017.1291195
pubmed: 28597798
Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC [published correction appears in Eur Heart J. 2016 Dec 30;:]. Eur Heart J. 2016;37(27):2129–2200. https://doi.org/10.1093/eurheartj/ehw128 .
Chawla LS, Eggers PW, Star RA, Kimmel PL. Acute kidney injury and chronic kidney disease as interconnected syndromes. N Engl J Med. 2014;371(1):58–66. https://doi.org/10.1056/NEJMra1214243 .
doi: 10.1056/NEJMra1214243
pubmed: 24988558
Damman K, Valente MA, Voors AA, O’Connor CM, van Veldhuisen DJ, Hillege HL. Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis. Eur Heart J. 2014;35(7):455–69. https://doi.org/10.1093/eurheartj/eht386 .
doi: 10.1093/eurheartj/eht386
pubmed: 24164864
Ahmad T, Jackson K, Rao VS, et al. Worsening Renal Function in Patients With Acute Heart Failure Undergoing Aggressive Diuresis Is Not Associated With Tubular Injury [published correction appears in Circulation. 2018 Jun 19;137(25):e853]. Circulation. 2018;137(19):2016–2028. https://doi.org/10.1161/circulationaha.117.030112 .
Rao VS, Ahmad T, Brisco-Bacik MA, et al. Renal effects of intensive volume removal in heart failure patients with preexisting worsening renal function. Circ Heart Fail. 2019;12(6):e005552. https://doi.org/10.1161/CIRCHEARTFAILURE.118.005552 .
doi: 10.1161/CIRCHEARTFAILURE.118.005552
pubmed: 31163974
pmcid: 6585463
Metra M, Davison B, Bettari L, et al. Is worsening renal function an ominous prognostic sign in patients with acute heart failure? The role of congestion and its interaction with renal function. Circ Heart Fail. 2012;5(1):54–62. https://doi.org/10.1161/CIRCHEARTFAILURE.111.963413 .
doi: 10.1161/CIRCHEARTFAILURE.111.963413
pubmed: 22167320
Stevenson LW, Perloff JK. The limited reliability of physical signs for estimating hemodynamics in chronic heart failure. JAMA. 1989;261(6):884–8.
doi: 10.1001/jama.1989.03420060100040
Gheorghiade M, Follath F, Ponikowski P, et al. Assessing and grading congestion in acute heart failure: a scientific statement from the acute heart failure committee of the heart failure association of the European Society of Cardiology and endorsed by the European Society of Intensive Care Medicine. Eur J Heart Fail. 2010;12(5):423–33. https://doi.org/10.1093/eurjhf/hfq045 .
doi: 10.1093/eurjhf/hfq045
pubmed: 20354029
Vaduganathan M, Greene SJ, Fonarow GC, Voors AA, Butler J, Gheorghiade M. Hemoconcentration-guided diuresis in heart failure. Am J Med. 2014;127(12):1154–9. https://doi.org/10.1016/j.amjmed.2014.06.009 .
doi: 10.1016/j.amjmed.2014.06.009
pubmed: 24937157
Coiro S, Rossignol P, Ambrosio G, et al. Prognostic value of residual pulmonary congestion at discharge assessed by lung ultrasound imaging in heart failure. Eur J Heart Fail. 2015;17(11):1172–81. https://doi.org/10.1002/ejhf.344 .
doi: 10.1002/ejhf.344
pubmed: 26417699
Adrogue HJ, Roehr EE, Roncoroni AJ. Contraction alkalosis during recovery of cardio-respiratory failure. Medicina (B Aires). 1974;34(2):133–8.
pubmed: 4851171
Grodin JL, Carter S, Bart BA, Goldsmith SR, Drazner MH, Tang WHW. Direct comparison of ultrafiltration to pharmacological decongestion in heart failure: a per-protocol analysis of CARRESS-HF. Eur J Heart Fail. 2018;20(7):1148–56. https://doi.org/10.1002/ejhf.1158 .
doi: 10.1002/ejhf.1158
pubmed: 29493059
Rosen RA, Julian BA, Dubovsky EV, Galla JH, Luke RG. On the mechanism by which chloride corrects metabolic alkalosis in man. Am J Med. 1988;84(3 Pt 1):449–58. https://doi.org/10.1016/0002-9343(88)90265-3 .
doi: 10.1016/0002-9343(88)90265-3
pubmed: 2450456
Van der Meer P, Postmus D, Ponikowski P, et al. The predictive value of short-term changes in hemoglobin concentration in patients presenting with acute decompensated heart failure. J Am Coll Cardiol. 2013;61(19):1973–1981. https://doi.org/10.1016/j.jacc.2012.12.050 .
Greene SJ, Gheorghiade M, Vaduganathan M, et al. Haemoconcentration, renal function, and post-discharge outcomes among patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial. Eur J Heart Fail. 2013;15(12):1401–11. https://doi.org/10.1093/eurjhf/hft110 .
doi: 10.1093/eurjhf/hft110
pubmed: 23845795
pmcid: 4199468
McCallum W, Tighiouart H, Testani JM, et al. Acute kidney function declines in the context of decongestion in acute decompensated heart failure. JACC Heart Fail. 2020;8(7):537–47. https://doi.org/10.1016/j.jchf.2020.03.009 .
doi: 10.1016/j.jchf.2020.03.009
pubmed: 32535124
Testani JM, Brisco MA, Chen J, McCauley BD, Parikh CR, Tang WH. Timing of hemoconcentration during treatment of acute decompensated heart failure and subsequent survival: importance of sustained decongestion. J Am Coll Cardiol. 2013;62(6):516–24. https://doi.org/10.1016/j.jacc.2013.05.027 .
doi: 10.1016/j.jacc.2013.05.027
pubmed: 23747773
pmcid: 3892152
Ritzema JL, Richards AM, Crozier IG, et al. Serial Doppler echocardiography and tissue Doppler imaging in the detection of elevated directly measured left atrial pressure in ambulant subjects with chronic heart failure. JACC Cardiovasc Imaging. 2011;4(9):927–34. https://doi.org/10.1016/j.jcmg.2011.07.004 .
doi: 10.1016/j.jcmg.2011.07.004
pubmed: 21920328
Porter TR, Shillcutt SK, Adams MS, et al. Guidelines for the use of echocardiography as a monitor for therapeutic intervention in adults: a report from the American Society of Echocardiography. J Am Soc Echocardiogr. 2015;28(1):40–56. https://doi.org/10.1016/j.echo.2014.09.009 .
doi: 10.1016/j.echo.2014.09.009
pubmed: 25559474
Jambrik Z, Monti S, Coppola V, et al. Usefulness of ultrasound lung comets as a nonradiologic sign of extravascular lung water. Am J Cardiol. 2004;93(10):1265–70. https://doi.org/10.1016/j.amjcard.2004.02.012 .
doi: 10.1016/j.amjcard.2004.02.012
pubmed: 15135701
Price S, Platz E, Cullen L, et al. Expert consensus document: echocardiography and lung ultrasonography for the assessment and management of acute heart failure. Nat Rev Cardiol. 2017;14(7):427–40. https://doi.org/10.1038/nrcardio.2017.56 .
doi: 10.1038/nrcardio.2017.56
pubmed: 28447662
pmcid: 5767080
Simon MA, Schnatz RG, Romeo JD, Pacella JJ. Bedside ultrasound assessment of jugular venous compliance as a potential point-of-care method to predict acute decompensated heart failure 30-day readmission. J Am Heart Assoc. 2018;7(15):e008184. https://doi.org/10.1161/JAHA.117.008184 .
doi: 10.1161/JAHA.117.008184
pubmed: 30371245
pmcid: 6201476
Öhman J, Harjola VP, Karjalainen P, Lassus J. Focused echocardiography and lung ultrasound protocol for guiding treatment in acute heart failure. ESC Heart Fail. 2018;5(1):120–8. https://doi.org/10.1002/ehf2.12208 .
doi: 10.1002/ehf2.12208
pubmed: 28960894
Kimura BJ, Demaria AN. Empowering physical examination: the “laying on” of ultrasound. JACC Cardiovasc Imaging. 2008;1(5):602–4. https://doi.org/10.1016/j.jcmg.2008.06.004 .
doi: 10.1016/j.jcmg.2008.06.004
pubmed: 19356488
Rivas-Lasarte M, Maestro A, Fernández-Martínez J, et al. Prevalence and prognostic impact of subclinical pulmonary congestion at discharge in patients with acute heart failure [published online ahead of print, 2020 Jul 7]. ESC Heart Fail. 2020. https://doi.org/10.1002/ehf2.12842 .
Fridman D, Cohen A, Robinson G et al. Point of care lung ultrasound predicts heart failure readmissions. Circulation: heart failure and cardiomyopathies. In: Proceedings from AHA Scientific Sessions 2019. Nov 11, 2019. Abstract 11609.
Olarte N, Jacobs M, Vincent L et al. A trial of pre-discharge point of care ultrasound for acute decompensated heart failure. Circulation: cardiovascular quality and outcomes. In: Proceedings from AHA Quality of Care and Outcomes Research (QCOR) 2020 Scientific Sessions; May 15, 2020. Abstract 346.
Huston JH, Ferre R, Pang PS, Chioncel O, Butler J, Collins S. Optimal endpoints of acute heart failure therapy. Am J Ther. 2018;25(4):e465–74. https://doi.org/10.1097/MJT.0000000000000792 .
doi: 10.1097/MJT.0000000000000792
pubmed: 29985825
pmcid: 6042977
Laliberte B, Reed BN, Devabhakthuni S, et al. Observation of patients transitioned to an oral loop diuretic before discharge and risk of readmission for acute decompensated heart failure. J Card Fail. 2017;23(10):746–52. https://doi.org/10.1016/j.cardfail.2017.06.008 .
doi: 10.1016/j.cardfail.2017.06.008
pubmed: 28688888
Schale S, Brambatti M, Hansen P et al. Transitioning patients to oral diuretics 24 hours before discharge from heart failure hospitalization does not improve 30 day outcomes. J Card Fail. In: Proceedings from the Heart Failure Society of America; Sep 13–16, 2019; Philadelphia, PA. Abstract 160.
Woodruff AE, Kelley AM, Hempel CA, Loeffler WJ, Echtenkamp CA, Hassan AK. Discharge diuretic dose and 30-day readmission rate in acute decompensated heart failure. Ann Pharmacother. 2016;50(6):437–45. https://doi.org/10.1177/1060028016637385 (Epub 2016 Mar 8).
doi: 10.1177/1060028016637385
pubmed: 26956954
Prather K, Harding T, Gabriel D, Mentz RJ, Anstrom KJ. TRANSFORM-HF Trial Protocol. https://clinicaltrials.gov/ct2/show/NCT03296813 . Accessed Nov 2020.